Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. In addition to our broad portfolio, we have an accomplished team of scientists, novel technology platforms and end-to-end capabilities from new target discovery to GMP manufacturing. We believe that combination therapies and a deep understanding of each patientâs cancer will be key drivers of success in substantially expanding the patient population benefiting from current immuno-oncology therapies. At Agenus, we believe we have assembled the capabilities to bring curative treatments to patients. Source
No articles found.
Novanta is a leading global supplier of core technology solutions that give medica...
Novanta is a leading global supplier of core te...
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Vaxart is focused on developing oral recombinant protein vaccines administered usi...
Vaxart is focused on developing oral recombinan...
Abeona Therapeutics is focused on developing and delivering gene therapy products ...
Abeona Therapeutics is focused on developing an...
NuVasive is a world leader in minimally invasive, procedurally integrated spine so...
NuVasive is a world leader in minimally invasiv...
ACS Global, Inc. engages in the collection, processing, and long-term storage of s...
ACS Global, Inc. engages in the collection, pro...
The discovery of immunosuppressive (anti-rejection) drugs has made possible life-s...
The discovery of immunosuppressive (anti-reject...
Join the National Investor Network and get the latest information with your interests in mind.